Related Experiment Video
Updated: May 25, 2025
MicroRNA Expression Profiles of Human iPS Cells, Retinal Pigment Epithelium Derived From iPS, and Fetal Retinal Pigment Epithelium
Published on: June 24, 2014
Retinopathy of Prematurity and MicroRNAs
Giuseppe Maria Albanese1, Giacomo Visioli1, Ludovico Alisi1
1Department of Sense Organs, Sapienza-University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.
Insights
MicroRNAs (miRNAs) are key regulators in Retinopathy of Prematurity (ROP), a condition causing infant blindness. miRNA-based therapies show promise for treating ROP by targeting neovascularization and inflammation.
Area of Science:
- Ophthalmology
- Molecular Biology
- Developmental Biology
Background:
- Retinopathy of Prematurity (ROP) is a significant cause of blindness in premature infants.
- ROP involves abnormal blood vessel growth (angiogenesis) and inflammation in the retina.
- Severe ROP can lead to retinal detachment and irreversible vision loss.
Purpose of the Study:
- To review the role of microRNAs (miRNAs) in the pathogenesis of Retinopathy of Prematurity.
- To explore the potential of miRNAs as diagnostic biomarkers for ROP.
- To evaluate miRNA-based therapeutic strategies for managing ROP.
Main Methods:
- Literature review of studies on miRNAs in ROP.
- Analysis of miRNA involvement in key ROP pathways like hypoxia response and VEGF signaling.
- Examination of preclinical data on miRNA-based therapies and delivery systems.
Main Results:
- Specific miRNAs (e.g., miR-210, miR-146a, miR-21) are implicated in ROP development.
- miRNA-based therapies targeting pathways like HIF-1α and VEGFA show potential in preclinical models.
- Nanoparticle delivery enhances the efficacy and specificity of miRNA therapeutics.
Conclusions:
- MicroRNAs play a crucial role in ROP pathogenesis and progression.
- miRNAs represent promising biomarkers for ROP diagnosis.
- miRNA-based therapies, potentially combined with anti-VEGF agents, offer a novel therapeutic avenue for ROP, pending clinical validation.
Abstract:
Retinopathy of Prematurity (ROP), a leading cause of blindness in preterm infants, arises from dysregulated angiogenesis and inflammation. Without timely intervention, ROP can progress to severe outcomes, including dense fibrovascular plaques and retinal detachment. MicroRNAs (miRNAs) regulate key pathways such as hypoxia response, VEGF signaling, and vascular remodeling. Studies have identified miRNAs (e.g., miR-210, miR-146a, and miR-21) as potential biomarkers and therapeutic targets. Preclinical evidence supports miRNA-based therapies (e.g., miR-18a-5p and miR-181a), targeting HIF-1α and VEGFA to mitigate neovascularization, with nanoparticle delivery systems enhancing stability and specificity. These strategies, combined with anti-VEGF agents, show significant potential for improving ROP management. While promising, miRNA therapies require validation in clinical trials to ensure safety and efficacy. This review discusses the role of miRNAs in ROP, highlighting their relevance as diagnostic and therapeutic tools.
Related Concept Videos
01:22MicroRNAs
01:32The Retina